Description

Fmoc-MMAE is a protective group-conjugated monomethyl auristatin E (MMAE), which is a potent tubulin inhibitor. Fmoc-MMAE can be used in the synthesis of ADC[1].-4°C (Powder, stored under nitrogen)-Applications-Cancer-programmed cell death-Formula-C54H77N5O9-Citation–References-[1]Pan D, et al. An antibody-drug conjugate targeting a GSTA glycosite-signature epitope of MUC1 expressed by non-small cell lung cancer. Cancer Med. 2020;9(24):9529-9540. -CASNumber-474645-26-6-MolecularWeight-940.22-Compound Purity-99.60-SMILES-CC[C@H](C)[C@@H]([C@@H](CC(N1[C@@H](CCC1)[C@@H]([C@@H](C)C(N[C@H](C)[C@@H](O)C2=CC=CC=C2)=O)OC)=O)OC)N(C([C@H](C(C)C)NC([C@H](C(C)C)N(C(OCC3C4=C(C=CC=C4)C5=C3C=CC=C5)=O)C)=O)=O)C-Research_Area-Cancer-Solubility-DMSO : ≥ 45 mg/mL-Target-ADC Cytotoxin;Microtubule/Tubulin-Isoform-Auristatin-Pathway-Antibody-drug Conjugate/ADC Related;Cell Cycle/DNA Damage;Cytoskeleton-MCE Product type-ADC Related